Characteristics of patients with severe, uncontrolled, eosinophilic asthma enrolled in a French cohort
Authors Aubier M, Thabut G, Fabry-Vendrand C
Received 13 April 2018
Accepted for publication 16 June 2018
Published 31 August 2018 Volume 2018:11 Pages 217—224
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Amrita Dosanjh
Michel Aubier,1–4 Gabriel Thabut,1–3,5 Caroline Fabry-Vendrand6
1Inserm UMR1152, Physiopathology and Epidemiology of Respiratory Diseases, Paris, France; 2Faculty of Medicine, Paris Diderot University, Paris, France; 3Laboratory of Excellence, INFLAMEX, Université Sorbonne Paris Cité and DHU FIRE, Paris, France; 4Pneumology A Department, Bichat-Claude-Bernard University Hospital, Paris, France; 5Pneumology B Department, Bichat-Claude-Bernard University Hospital, Paris, France; 6Epidemiology and Research Partnerships, AstraZeneca, Courbevoie, France
Background and objective: Benralizumab (Fasenra™) has recently been approved as add-on maintenance treatment for adult patients with severe eosinophilic asthma inadequately controlled despite high-dosage inhaled corticosteroids plus long-acting β2-agonists. We aimed to identify and describe the clinical characteristics and disease burden of patients with severe, uncontrolled, eosinophilic asthma in France who may be eligible for treatment with benralizumab.
Patients and methods: This was a retrospective analysis of a prospective, noninterventional, observational study of patients in France enrolled in the Asthma and Bronchial Obstruction Cohort (COBRA). First, we selected adult patients with severe asthma, a documented blood eosinophil count, 12 months of baseline data, and 12 months of follow-up data. Of these study-eligible patients, we next determined the prevalence and described the clinical characteristics and disease burden of patients who would be eligible to receive benralizumab, namely those with ≥2 asthma exacerbations in the previous 12 months and a blood eosinophil count ≥300/μL who were receiving high-dosage inhaled corticosteroids/long-acting β2-agonists.
Results: Of the 441 patients eligible for this study, 85 (19%) met the criteria for benralizumab therapy. At study inclusion, benralizumab-eligible patients had a smaller prebronchodilator forced expiratory volume in 1 second and less effective asthma control compared with benralizumab-ineligible patients. During the 12-month follow-up period, benralizumab-eligible patients had greater frequencies of asthma exacerbations and hospitalizations compared with benralizumab-ineligible patients.
Conclusion: Of patients with severe asthma, approximately 20% were qualified for benralizumab treatment. Benralizumab-eligible patients had increased bronchial obstruction, worse asthma control, and a greater frequency of asthma exacerbations and hospitalizations during follow-up care compared with benralizumab-ineligible patients, demonstrating inadequate disease control for these patients.
Keywords: COBRA, benralizumab, biologic, eosinophilia, France
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]